Delayed Antibiotic Therapy in Non-severe Ventilator Acquired Pneumonia (VAP) (DELAVAP)

Nantes University Hospital (NUH)

Status: Completed

Conditions: Ventilator Associated Pneumonia; Critical Care; Antibiotic Therapy

Treatments: Other: Restrictive antibiotic strategy; Other: Aggressive antibiotic strategy

Study type: Observational

Funder types: Other

Identifiers

NCT05205525

MR_DELAVAP

Details and patient eligibility

About

This retro-prospective monocentric observational study compare the impact of the implementation of a restrictive (delayed) versus aggressive (immediate) antibiotic strategy for Ventilator Acquired Pneumonia suspicion without severity symptoms.

Full description

Ventilator acquired pneumonia (VAP) is the leading cause of nosocomial infection in intensive care patients, and has been associated with increased antibiotic consumption, increased morbidity and mortality. VAP diagnosis is difficult due to subjective or non-specific criteria. Delaying antibiotic treatment for VAP suspicion without severity symptoms raises question since the probability of VAP diagnosis, as well as the risk of delaying treatment, is very uncertain. It may nonetheless limit the environmental impact of antibiotic use which is a public health concern. We compared antibiotic sparing and patient outcome, before and after the implementation of a restrictive (delayed) antibiotic strategy versus an aggressive (immediate) antibiotic strategy in VAP suspicion without severity symptoms.

Enrollment: 87 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Under mechanical ventilation from more than 48 hours
• Suspected for a ventilator acquired pneumonia, requiring a distal pulmonary bacterial sample

Exclusion criteria

• New or worsening shock requiring vasopressor
• New or worsening severe hypoxemia (PaO2/FiO2<150 in FiO2≥60% and peep 10)
• Patient under veno-veinous extracorporeal membrane oxygenation
• Neutropenia <1G/L or immunosuppressive treatment (including corticosteroids >6 months or >0.5mg/kg/j)
• Disease (endocarditis, spondylodyscitis, deep abcedation...) requiring prolonged antibiotic therapy

Trial design

87 participants in 2 patient groups

Restrictive antibiotic strategy

Treatment:

Other: Restrictive antibiotic strategy

Aggressive (immediate) antibiotic strategy

Treatment:

Other: Aggressive antibiotic strategy